UGT1A1Your two copies: *1/*28+*60+*80
Intermediate metabolizer
One copy works and one works less well.
Clears bilirubin and some drugs, such as the cancer drug irinotecan.
This result doesn't change the label.
Example report. Made from Leslie Knope's DNA data so you can see what yours will look like. Get your own report
Oncology · ChemotherapiesExample report
Pazopanib
Votrient
Use as directed
Your UGT1A1 gene works a bit less than average. The FDA gives no dose change for your result, so the usual dose is used.
The genes behind this label
The guidelines read one gene for pazopanib. Each card shows the two copies this person inherited and what they mean.
What the guidelines say
What each guideline says about your result.
UGT1A1Intermediate metabolizer
- In plain words
- Your UGT1A1 gene works a bit less than average. The FDA gives no dose change for your result, so the usual dose is used.
- What it means
- No FDA guidance for your genotype
- What the label suggests
- Initiate therapy with recommended starting dose.
About pazopanib
Pazopanib (Votrient) is a kinase inhibitor tablet for advanced kidney cancer (renal cell carcinoma) and for advanced soft tissue sarcoma after earlier chemotherapy.
- Used for
- Advanced renal cell carcinoma; advanced soft tissue sarcoma in adults who have had chemotherapy
Others in oncology
Compare all 13 oncology- BelinostatBeleodaq Use as directed
- BelzutifanWelireg Use as directed
- CapecitabineXeloda, Xitabin, Kapetral Use as directed
- ErdafitinibBalversa Use as directed
- FluorouracilAdrucil, Carac Use as directed
- GefitinibIressa Use with caution
- IrinotecanCamptosar, Onivyde Use as directed
- MercaptopurinePurinethol Use as directed
Don't change a dose on your own. Bring this report to your prescriber or pharmacist. They can weigh it with everything else they know about you.